Modality
siRNA
MOA
FXIai
Target
WEE1
Pathway
PD-1/PD-L1
OCD
Development Pipeline
Preclinical
~Aug 2019
→ ~Nov 2020
Phase 1
Feb 2021
→ Sep 2027
Phase 1Current
NCT05256007
917 pts·OCD
2021-02→2027-09·Active
917 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-09-271.5y awayInterim· OCD
Trial Timeline
2021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P1
Active
Catalysts
Interim
2027-09-27 · 1.5y away
OCD
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05256007 | Phase 1 | OCD | Active | 917 | EASI-75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| NVS-6360 | Novartis | Approved | CD38 | |
| MRK-3745 | Merck & Co | Phase 2 | WRN | |
| AZN-1715 | AstraZeneca | Phase 3 | AHR | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| TAK-8730 | Takeda | Phase 2 | VEGF | |
| TAK-2403 | Takeda | Phase 2 | WEE1 | |
| Sovacapivasertib | Amgen | Phase 3 | WEE1 | |
| Semazasiran | BeiGene | Phase 1 | PD-1 | |
| Fixaglumide | Genmab | Phase 2/3 | WEE1 |